@article{4c2aeeb63e86407b908556c92415d1b1,
title = "Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation ofschizophrenia",
abstract = "This double-blind, randomized, multicenter study investigated the use of divalproex with an antipsychotic agent in patients hospitalized for acute exacerbation of schizophrenia. Patients (n = 249) who met DSM-IV criteria for schizophrenia were randomly assigned toreceive olanzapine monotherapy, risperidonemonotherapy, divalproex plus olanzapine, or divalproex plus risperidone for 28 days.Divalproex was initiated at 15 mg/kg/day and titrated over 12 days to a maximum dosage of 30 mg/kg/day. Olanzapine and risperidone, were, respectively, initiated at 5 and 2 mg/day and were titrated over the first 6 days to respective target fixed daily dosages of 15 and6mg/day. Improvements from baseline were observed at allevaluation points throughout the 28-day treatment period in the twocombination therapy and the two antipsychotic monotherapy groups, with statistically significant treatment differences favoringcombination therapy as soon as day 3 for Positive and Negative Syndrome Scale (PANSS) totalscore, derived Brief Psychiatric RatingScale (BPRSd) totalscore, as wellas PANSS and BPRSd subscales. These findings were confirmed inpost hocrepeated-measures analysesof variance in which treatment differences favoring combination therapy were observed for PANSS total (p = 0.020) and PANSS positivescale scores (p = 0.002). Both combination therapy and antipsychotic monotherapy were welltolerated. Treatment with divalproex incombination with an atypicalantipsychotic agent resulted in earlier improvements in a range of psychotic symptoms among acutelyhospitalized patients with schizophrenia. Further evaluation is warranted to confirm these findings.",
keywords = "Divalproex, Olanzapine, Psychosis, Risperidone, Schizophrenia",
author = "Casey, {Daniel E.} and Daniel, {David G.} and Wassef, {Adel A.} and Tracy, {Katherine A.} and Patricia Wozniak and Sommerville, {Kenneth W.}",
note = "Funding Information: This study was supported by a grant from Abbott Laboratories, Abbott Park, IL. We wish to thank John Kane from Long Island Jewish Medical Center, Glen Oaks, NY,and Carol Tamminga, from the University of Maryland, Baltimore, MD, for their contributions to the design of this study. We would also like to thank the other members of the Depakote Psychosis Group, as follows, for their enrollment of patients and participation in this study: George W Ainslie, Coatesville VA Medical Center, Coatesville, PA; Louise M Beckett, IPS Research Company, Oklahoma City, OK; Jeffrey A Borenstein, Holliswood Hospital, Holliswood, NY; Gary K Borrell, Department of Psychiatry, University of Oklahoma, Oklahoma City, OK; Anthony Braus, Wm S Middleton Memorial VA Hospital, Madison, WI; David W Brown, Community Clinical Research, Austin, TX; John S Carman, Carman Research, Smyrna, GA; Leslie L Citrome, Nathan Kline Institute, Orangeburg, NY; Ram Gopalan, Clinical Studies–Washington, Falls Church, VA; Mark B Hamner, Ralph H Johnson VA Medical Center, Charleston, SC; Richard R Jaffe, Belmont Center for Comprehensive Treatment, Philadelphia, PA; Mary Ann Knesevich, St. Paul Medical Center at Southwestern Medical Center, Dallas, TX; Michael D Lesem, Claghorn –Lesem Research Clinic, Bellaire, TX; Jean-Pierre Lindenmayer, Manhattan Psychiatric Center, New York, NY; Robert E Litman, Center for Behavioral Health, Rockville, MD; HE Logue, Birmingham Psychiatry Pharmaceutical Studies, Birmingham, AL; Charles H Merideth, Affiliated Research Institute, San Diego, CA; Alexander L Miller, San Antonio State Hospital, San Antonio, TX; Steven G Potkin, UC-Irvine Medical Center, Orange, CA; Robert A Riesenberg, Atlanta Center for Medical Research, Atlanta, GA; Murray H Rosenthal, Behavioral and Medicine Research, San Diego, CA; Alan L Schneider, Cedars Sinai Medical Center, Los Angeles, CA; Rajiv P Sharma, Psychiatric Institute, Chicago, IL; Samuel D Shillcutt, Central State Hospital, Milledgeville, GA; Andre Tapp, VA Riget, Sound Health Care System, Tacoma, WA; Marshall R Thomas, Colorado Psychiatric Hospital, Denver, CO; Tram K Tran-Johnson, CNRI, San Diego, CA; Richard H Weisler, Raleigh, NC.",
year = "2003",
month = jan,
doi = "10.1038/sj.npp.1300023",
language = "English (US)",
volume = "28",
pages = "182--192",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "1",
}